Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Sector

Industry

CEO

Taelman, Olivier

Employees

184

Website

www.nyxoah.com

IPO Date

Headquarters

Rue Edouard Belin 12, Mont-Saint-Guibert, Walloon Brabant, 1435, Belgium

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Nyxoah NYXH

Nyxoah Earnings Call Summary

Nyxoah Earnings

Transcripts

Events

About Nyxoah SA

Nyxoah
NYXH